Form 4: Rani Therapeutics Director Dennis Ausiello Granted 50,000 Stock Options

Dennis A. Ausiello, a Director at Rani Therapeutics Holdings, Inc., was granted 50,000 stock options with an exercise price of $0.62 per share, vesting over one year or upon specific corporate events.

Summary

• Dennis A. Ausiello, a Director of Rani Therapeutics Holdings, Inc. (RANI), was granted 50,000 Director Stock Options on May 28, 2025.
• The exercise price for these options is $0.62 per share.
• The options are set to expire on May 27, 2035.
• The shares subject to the option will vest in full on the first anniversary of the grant date (May 28, 2026), provided the recipient maintains Continuous Service as defined in the Company's 2021 Equity Incentive Plan.
• Alternatively, the options will vest in full earlier upon the occurrence of the Company's next annual stockholder meeting or a Change in Control, as defined in the 2021 Equity Incentive Plan.
• Following this transaction, Dennis A. Ausiello beneficially owns 50,000 derivative securities directly.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. This is a routine compensation filing (Form 4) for a director receiving stock options, which aligns their interests with shareholders. It does not contain significant positive or negative financial news beyond the compensation itself.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages continued service and commitment from the director.

Future Outlook

The vesting schedule of the stock options indicates a future commitment from the director to the company's performance, with full vesting expected on the first anniversary of the grant date or earlier under specific corporate events.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, as well as across publicly traded companies, to incentivize leadership and align their financial interests with long-term shareholder value.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across industries, including biotechnology, to attract and retain qualified board members.
• The vesting schedule, which includes time-based vesting and accelerated vesting upon specific corporate events (like an annual meeting or change in control), is typical for equity awards to directors and executives, aligning with corporate governance best practices.

Corporate Governance

Related Party Transactions

• The grant of stock options to Dennis A. Ausiello, a Director, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options to a director aims to align the director's financial interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: While this specific grant is to a director, it reflects the company's broader equity incentive plan, which may also apply to employees, potentially boosting morale and retention.

Next Steps

• The options will vest in full on May 28, 2026, or earlier upon the Company's next annual stockholder meeting or a Change in Control, subject to continuous service.
• Upon vesting, the director will have the right to exercise the options to purchase Class A Common Stock at the specified exercise price.

Key Dates

Keywords

Rani Therapeutics Holdings Inc, RANI, Stock Options, Director Compensation, SEC Form 4, Beneficial Ownership, Equity Incentive Plan, Insider Transaction